HC Wainwright Issues Optimistic Outlook for argenx Earnings

argenx SE (NASDAQ:ARGX) – HC Wainwright boosted their Q3 2025 earnings per share (EPS) estimates for argenx in a research report issued to clients and investors on Friday, February 28th. HC Wainwright analyst D. Tsao now expects that the company will post earnings per share of $1.68 for the quarter, up from their previous forecast of $1.65. HC Wainwright has a “Buy” rating and a $720.00 price target on the stock. The consensus estimate for argenx’s current full-year earnings is $3.13 per share. HC Wainwright also issued estimates for argenx’s FY2025 earnings at $6.50 EPS.

argenx (NASDAQ:ARGX) last posted its earnings results on Thursday, February 27th. The company reported $1.58 EPS for the quarter, topping the consensus estimate of $0.98 by $0.60. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The firm had revenue of $761.22 million for the quarter, compared to analyst estimates of $678.52 million.

Several other brokerages have also commented on ARGX. JMP Securities raised their price objective on argenx from $606.00 to $696.00 and gave the company a “market outperform” rating in a report on Tuesday, January 14th. Piper Sandler raised their price objective on argenx from $620.00 to $725.00 and gave the company an “overweight” rating in a report on Tuesday, January 7th. Wolfe Research upgraded argenx from a “peer perform” rating to an “outperform” rating and set a $697.00 target price on the stock in a research report on Tuesday, November 12th. JPMorgan Chase & Co. raised their target price on argenx from $640.00 to $670.00 and gave the company an “overweight” rating in a research report on Monday, November 4th. Finally, Scotiabank upgraded argenx from a “sector perform” rating to a “sector outperform” rating and lifted their price objective for the stock from $439.00 to $715.00 in a research report on Tuesday, November 5th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $661.17.

argenx Trading Down 0.3 %

Shares of ARGX opened at $622.61 on Monday. argenx has a 12 month low of $349.86 and a 12 month high of $678.21. The stock’s 50 day moving average is $642.62 and its two-hundred day moving average is $591.22. The firm has a market cap of $37.83 billion, a P/E ratio of -707.51 and a beta of 0.58.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Stifel Financial Corp grew its stake in argenx by 15.3% during the 3rd quarter. Stifel Financial Corp now owns 8,832 shares of the company’s stock worth $4,788,000 after purchasing an additional 1,170 shares in the last quarter. FMR LLC boosted its position in shares of argenx by 35.9% during the 3rd quarter. FMR LLC now owns 4,793,472 shares of the company’s stock worth $2,598,445,000 after acquiring an additional 1,265,486 shares in the last quarter. Simplify Asset Management Inc. boosted its position in shares of argenx by 64.0% during the 3rd quarter. Simplify Asset Management Inc. now owns 2,419 shares of the company’s stock worth $1,311,000 after acquiring an additional 944 shares in the last quarter. Stephens Inc. AR acquired a new position in shares of argenx during the 4th quarter worth about $310,000. Finally, Ritholtz Wealth Management boosted its position in shares of argenx by 85.5% during the 4th quarter. Ritholtz Wealth Management now owns 898 shares of the company’s stock worth $552,000 after acquiring an additional 414 shares in the last quarter. 60.32% of the stock is owned by institutional investors and hedge funds.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.